We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Cannabis Stocks CRON & APHA Are Moving in Opposite Directions
Read MoreHide Full Article
Shares of Cronos Group (CRON - Free Report) and Aphria extended their recent moves in opposite directions on Tuesday morning, as investors continued to digest major headlines related to the popular cannabis companies.
Cronos shares, which added more than 11% on Monday, were up another 4% in early morning trading today after the company confirmed it has been in talks with tobacco giant Altria (MO - Free Report) about a potential investment. Reports revealing these discussions first surfaced yesterday.
An investment or takeover from Altria could be exciting news for Cronos investors and the broader marijuana industry. Canadian legalization and listings on U.S. exchanges, among other factors, have helped cannabis become an exciting new investing segment, but there is still a sense of uncertainty that involvement from an established leader like Altria might help solve.
Still, any potential deal, Cronos said in a statement today, is far from guaranteed.
“No agreement has been reached with respect to any such transaction and there can be no assurance such discussions will lead to an investment or other transaction involving the companies,” wrote Cronos Group.
Meanwhile, Aphria shares fell more than 20% on Tuesday morning, extending volatility which saw the stock lose almost 28% in the previous session. Aphria has been battered by a short-seller’s accusation that a recent deal to buy LATAM Holdings, a Columbia-based medical cannabis producer, was “largely worthless” and served only to benefit insiders.
According to Quintessential Capital Management’s Hindenburg Research, Aphria used cash from dilutive share issuances to purchase LATAM at an over-priced valuation, effectively diverting millions of dollars “from shareholders into their own pockets.”
Aphria steadfastly denied the allegations on Monday morning. In a press release, Aphria called the report a “malicious and self-serving attempt” to manipulate its stock price.
As for the LATAM acquisition, Aphria said that its board of directors “received financial advice and a fairness opinion from a reputable firm that the consideration to be offered by Aphria in respect of the transaction was fair, from a financial point of view, to Aphria and its shareholders.”
The drama underscores the aforementioned uncertainty of today’s cannabis business and has dragged Aphria shares lower, while many of its industry peers have surged on the hopes of major M&A deals.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Why Cannabis Stocks CRON & APHA Are Moving in Opposite Directions
Shares of Cronos Group (CRON - Free Report) and Aphria extended their recent moves in opposite directions on Tuesday morning, as investors continued to digest major headlines related to the popular cannabis companies.
Cronos shares, which added more than 11% on Monday, were up another 4% in early morning trading today after the company confirmed it has been in talks with tobacco giant Altria (MO - Free Report) about a potential investment. Reports revealing these discussions first surfaced yesterday.
An investment or takeover from Altria could be exciting news for Cronos investors and the broader marijuana industry. Canadian legalization and listings on U.S. exchanges, among other factors, have helped cannabis become an exciting new investing segment, but there is still a sense of uncertainty that involvement from an established leader like Altria might help solve.
Still, any potential deal, Cronos said in a statement today, is far from guaranteed.
“No agreement has been reached with respect to any such transaction and there can be no assurance such discussions will lead to an investment or other transaction involving the companies,” wrote Cronos Group.
Meanwhile, Aphria shares fell more than 20% on Tuesday morning, extending volatility which saw the stock lose almost 28% in the previous session. Aphria has been battered by a short-seller’s accusation that a recent deal to buy LATAM Holdings, a Columbia-based medical cannabis producer, was “largely worthless” and served only to benefit insiders.
According to Quintessential Capital Management’s Hindenburg Research, Aphria used cash from dilutive share issuances to purchase LATAM at an over-priced valuation, effectively diverting millions of dollars “from shareholders into their own pockets.”
Aphria steadfastly denied the allegations on Monday morning. In a press release, Aphria called the report a “malicious and self-serving attempt” to manipulate its stock price.
As for the LATAM acquisition, Aphria said that its board of directors “received financial advice and a fairness opinion from a reputable firm that the consideration to be offered by Aphria in respect of the transaction was fair, from a financial point of view, to Aphria and its shareholders.”
The drama underscores the aforementioned uncertainty of today’s cannabis business and has dragged Aphria shares lower, while many of its industry peers have surged on the hopes of major M&A deals.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>